Chuanjie Zhang1,2, Yuxiao Zheng3, Xiao Li3, Xin Hu4, Feng Qi5, Jun Luo6. 1. Department of Urinary Surgery, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China. 2. Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China. 3. Department of Urology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China. 4. Department of Urology, the First Affiliated Hospital of Nanjing Medical University, Nanjing 210029, China. 5. First Clinical Medical College of Nanjing Medical University, Nanjing 210029, China. 6. Department of Urology, Shanghai Fourth People's Hospital affiliated to Tongji University School of Medicine, Shanghai 200081, China.
Abstract
BACKGROUND: The papillary renal cell carcinoma (pRCC) is a rare subtype of renal cell carcinoma with limited investigation. Our study aimed to explore a robust signature to predict the prognosis of pRCC from the perspective of mutation profiles. METHODS: In this study, we downloaded the simple nucleotide variation data of 288 pRCC samples from The Cancer Genome Atlas (TCGA) database. "GenVisR" package was utilized to visualize gene mutation profiles in pRCC. The PPI network was conducted based on the STRING database and the modification was performed via Cytoscape software (Version 3.7.1). Top 50 mutant genes were selected and Cox regression method was conducted to identify the hub prognostic mutant signature in pRCC using "survival" package. Mutation Related Signature (MRS) risk score was established by multivariate Cox regression method. Receiver Operating Characteristic (ROC) curve drawn by "timeROC" was conducted to assess the predictive accuracy of overall survival (OS) and Kaplan-Meier analysis was then performed. Relationships between mutants and expression levels were compared by Wilcox rank-sum test. Function enrichment pathway analysis for mutated genes was performed by "org.Hs.eg.db", "clusterProfiler", "ggplot2" and "enrichplot" packages. Gene Set Enrichment Analysis was exploited using the MRS as the phenotypes, which worked based on the JAVA platform. All statistical analyses were achieved by R software (version 3.5.2). P value <0.05 was considered to be significant. RESULTS: The mutation landscape in waterfall plot revealed that a list of 49 genes that were mutated in more than 10 samples, of which 6 genes (TTN, MUC16, KMT2C, MET, OBSCN, LRP2) were mutated in more than 20 samples. Besides, non-synonymous was the most frequent mutation effect, and missense mutation was one of the most common mutation types in mutated genes across 248 samples. The AUC of MRS model consisted of 17 prognostic mutant signatures was 0.907 in 3-year OS prediction. Moreover, pRCC patients with high level of MRS showed the worse survival outcomes compared with that in low-level MRS group (P=0). In addition, correlation analysis indicated that 6 mutated genes (BAP1, OBSCN, NF2, SETD2, PBRM1, DNAH1) were significantly associated with corresponding expression levels. Last, functional enriched pathway analysis showed that these mutant genes were involved in multiple cancer-related crosstalk, including PI3K-AKT signaling pathway, JAK-STAT signaling pathway, extracellular matrix (ECM)-receptor interaction or cell cycle. CONCLUSIONS: In summary, our study was the first attempt to explore the mutation-related signature for predicting survival outcomes of pRCC based on the high-throughput data, which might provide valuable information for further uncovering the molecular pathogenesis in pRCC. 2019 Annals of Translational Medicine. All rights reserved.
BACKGROUND: The papillary renal cell carcinoma (pRCC) is a rare subtype of renal cell carcinoma with limited investigation. Our study aimed to explore a robust signature to predict the prognosis of pRCC from the perspective of mutation profiles. METHODS: In this study, we downloaded the simple nucleotide variation data of 288 pRCC samples from The Cancer Genome Atlas (TCGA) database. "GenVisR" package was utilized to visualize gene mutation profiles in pRCC. The PPI network was conducted based on the STRING database and the modification was performed via Cytoscape software (Version 3.7.1). Top 50 mutant genes were selected and Cox regression method was conducted to identify the hub prognostic mutant signature in pRCC using "survival" package. Mutation Related Signature (MRS) risk score was established by multivariate Cox regression method. Receiver Operating Characteristic (ROC) curve drawn by "timeROC" was conducted to assess the predictive accuracy of overall survival (OS) and Kaplan-Meier analysis was then performed. Relationships between mutants and expression levels were compared by Wilcox rank-sum test. Function enrichment pathway analysis for mutated genes was performed by "org.Hs.eg.db", "clusterProfiler", "ggplot2" and "enrichplot" packages. Gene Set Enrichment Analysis was exploited using the MRS as the phenotypes, which worked based on the JAVA platform. All statistical analyses were achieved by R software (version 3.5.2). P value <0.05 was considered to be significant. RESULTS: The mutation landscape in waterfall plot revealed that a list of 49 genes that were mutated in more than 10 samples, of which 6 genes (TTN, MUC16, KMT2C, MET, OBSCN, LRP2) were mutated in more than 20 samples. Besides, non-synonymous was the most frequent mutation effect, and missense mutation was one of the most common mutation types in mutated genes across 248 samples. The AUC of MRS model consisted of 17 prognostic mutant signatures was 0.907 in 3-year OS prediction. Moreover, pRCC patients with high level of MRS showed the worse survival outcomes compared with that in low-level MRS group (P=0). In addition, correlation analysis indicated that 6 mutated genes (BAP1, OBSCN, NF2, SETD2, PBRM1, DNAH1) were significantly associated with corresponding expression levels. Last, functional enriched pathway analysis showed that these mutant genes were involved in multiple cancer-related crosstalk, including PI3K-AKT signaling pathway, JAK-STAT signaling pathway, extracellular matrix (ECM)-receptor interaction or cell cycle. CONCLUSIONS: In summary, our study was the first attempt to explore the mutation-related signature for predicting survival outcomes of pRCC based on the high-throughput data, which might provide valuable information for further uncovering the molecular pathogenesis in pRCC. 2019 Annals of Translational Medicine. All rights reserved.
Authors: C Ponzetto; A Bardelli; Z Zhen; F Maina; P dalla Zonca; S Giordano; A Graziani; G Panayotou; P M Comoglio Journal: Cell Date: 1994-04-22 Impact factor: 41.582
Authors: M Shriver; K M Stroka; M I Vitolo; S Martin; D L Huso; K Konstantopoulos; A Kontrogianni-Konstantopoulos Journal: Oncogene Date: 2014-11-10 Impact factor: 9.867
Authors: Wenfeng Fang; Yuxiang Ma; Jiani C Yin; Shaodong Hong; Huaqiang Zhou; Ao Wang; Fufeng Wang; Hua Bao; Xue Wu; Yunpeng Yang; Yan Huang; Hongyun Zhao; Yang W Shao; Li Zhang Journal: Clin Cancer Res Date: 2019-05-13 Impact factor: 12.531
Authors: James J Hsieh; David Chen; Patricia I Wang; Mahtab Marker; Almedina Redzematovic; Ying-Bei Chen; S Duygu Selcuklu; Nils Weinhold; Nancy Bouvier; Kety H Huberman; Umesh Bhanot; Michael S Chevinsky; Parul Patel; Patrizia Pinciroli; Helen H Won; Daoqi You; Agnes Viale; William Lee; A Ari Hakimi; Michael F Berger; Nicholas D Socci; Emily H Cheng; Jennifer Knox; Martin H Voss; Maurizio Voi; Robert J Motzer Journal: Eur Urol Date: 2016-10-15 Impact factor: 20.096
Authors: W Marston Linehan; Paul T Spellman; Christopher J Ricketts; Chad J Creighton; Suzanne S Fei; Caleb Davis; David A Wheeler; Bradley A Murray; Laura Schmidt; Cathy D Vocke; Myron Peto; Abu Amar M Al Mamun; Eve Shinbrot; Anurag Sethi; Samira Brooks; W Kimryn Rathmell; Angela N Brooks; Katherine A Hoadley; A Gordon Robertson; Denise Brooks; Reanne Bowlby; Sara Sadeghi; Hui Shen; Daniel J Weisenberger; Moiz Bootwalla; Stephen B Baylin; Peter W Laird; Andrew D Cherniack; Gordon Saksena; Scott Haake; Jun Li; Han Liang; Yiling Lu; Gordon B Mills; Rehan Akbani; Mark D M Leiserson; Benjamin J Raphael; Pavana Anur; Donald Bottaro; Laurence Albiges; Nandita Barnabas; Toni K Choueiri; Bogdan Czerniak; Andrew K Godwin; A Ari Hakimi; Thai H Ho; James Hsieh; Michael Ittmann; William Y Kim; Bhavani Krishnan; Maria J Merino; Kenna R Mills Shaw; Victor E Reuter; Ed Reznik; Carl S Shelley; Brian Shuch; Sabina Signoretti; Ramaprasad Srinivasan; Pheroze Tamboli; George Thomas; Satish Tickoo; Kenneth Burnett; Daniel Crain; Johanna Gardner; Kevin Lau; David Mallery; Scott Morris; Joseph D Paulauskis; Robert J Penny; Candace Shelton; W Troy Shelton; Mark Sherman; Eric Thompson; Peggy Yena; Melissa T Avedon; Jay Bowen; Julie M Gastier-Foster; Mark Gerken; Kristen M Leraas; Tara M Lichtenberg; Nilsa C Ramirez; Tracie Santos; Lisa Wise; Erik Zmuda; John A Demchok; Ina Felau; Carolyn M Hutter; Margi Sheth; Heidi J Sofia; Roy Tarnuzzer; Zhining Wang; Liming Yang; Jean C Zenklusen; Jiashan Zhang; Brenda Ayala; Julien Baboud; Sudha Chudamani; Jia Liu; Laxmi Lolla; Rashi Naresh; Todd Pihl; Qiang Sun; Yunhu Wan; Ye Wu; Adrian Ally; Miruna Balasundaram; Saianand Balu; Rameen Beroukhim; Tom Bodenheimer; Christian Buhay; Yaron S N Butterfield; Rebecca Carlsen; Scott L Carter; Hsu Chao; Eric Chuah; Amanda Clarke; Kyle R Covington; Mahmoud Dahdouli; Ninad Dewal; Noreen Dhalla; Harsha V Doddapaneni; Jennifer A Drummond; Stacey B Gabriel; Richard A Gibbs; Ranabir Guin; Walker Hale; Alicia Hawes; D Neil Hayes; Robert A Holt; Alan P Hoyle; Stuart R Jefferys; Steven J M Jones; Corbin D Jones; Divya Kalra; Christie Kovar; Lora Lewis; Jie Li; Yussanne Ma; Marco A Marra; Michael Mayo; Shaowu Meng; Matthew Meyerson; Piotr A Mieczkowski; Richard A Moore; Donna Morton; Lisle E Mose; Andrew J Mungall; Donna Muzny; Joel S Parker; Charles M Perou; Jeffrey Roach; Jacqueline E Schein; Steven E Schumacher; Yan Shi; Janae V Simons; Payal Sipahimalani; Tara Skelly; Matthew G Soloway; Carrie Sougnez; Angela Tam; Donghui Tan; Nina Thiessen; Umadevi Veluvolu; Min Wang; Matthew D Wilkerson; Tina Wong; Junyuan Wu; Liu Xi; Jane Zhou; Jason Bedford; Fengju Chen; Yao Fu; Mark Gerstein; David Haussler; Katayoon Kasaian; Phillip Lai; Shiyun Ling; Amie Radenbaugh; David Van Den Berg; John N Weinstein; Jingchun Zhu; Monique Albert; Iakovina Alexopoulou; Jeremiah J Andersen; J Todd Auman; John Bartlett; Sheldon Bastacky; Julie Bergsten; Michael L Blute; Lori Boice; Roni J Bollag; Jeff Boyd; Erik Castle; Ying-Bei Chen; John C Cheville; Erin Curley; Benjamin Davies; April DeVolk; Rajiv Dhir; Laura Dike; John Eckman; Jay Engel; Jodi Harr; Ronald Hrebinko; Mei Huang; Lori Huelsenbeck-Dill; Mary Iacocca; Bruce Jacobs; Michael Lobis; Jodi K Maranchie; Scott McMeekin; Jerome Myers; Joel Nelson; Jeremy Parfitt; Anil Parwani; Nicholas Petrelli; Brenda Rabeno; Somak Roy; Andrew L Salner; Joel Slaton; Melissa Stanton; R Houston Thompson; Leigh Thorne; Kelinda Tucker; Paul M Weinberger; Cynthia Winemiller; Leigh Anne Zach; Rosemary Zuna Journal: N Engl J Med Date: 2015-11-04 Impact factor: 91.245
Authors: Zachary L Skidmore; Alex H Wagner; Robert Lesurf; Katie M Campbell; Jason Kunisaki; Obi L Griffith; Malachi Griffith Journal: Bioinformatics Date: 2016-06-10 Impact factor: 6.937